IGF-1 Sex- and Cycle-Related Differences: Normal Ranges, Optimal Levels, and What They Mean for Your Lab Work

What IGF-1 Actually Measures

Insulin-like growth factor 1 is the primary downstream effector of pituitary growth hormone. The liver produces most circulating IGF-1 in response to GH binding to hepatocyte receptors. Because GH itself pulses every 3 to 5 hours and has a half-life of roughly 20 minutes, clinicians use IGF-1 as the practical stand-in for integrated 24-hour GH activity. IGF-1 has a half-life of 12 to 15 hours in plasma, making it far more stable for routine blood draws.

The GH-IGF-1 Axis in Brief

GH secreted by the anterior pituitary travels to the liver and binds GH receptors. The liver responds by secreting IGF-1, which feeds back to suppress further GH release. This negative feedback loop means that anything disrupting liver function, whether oral estrogen use, caloric restriction, or hepatic disease, can lower IGF-1 independent of actual GH secretion. A 2018 paper in the Journal of Clinical Endocrinology and Metabolism confirmed that portal insulin concentration is also a key permissive factor for hepatic IGF-1 synthesis, explaining why fasting or insulin resistance can suppress IGF-1 even when GH pulse amplitude is normal [1].

Why Reference Ranges Are Not Universal

Commercial laboratories publish reference intervals derived from healthy control populations. Quest Diagnostics and LabCorp each stratify their intervals by sex and five-year age bands. Comparing a result from one laboratory to another laboratory's range is a common clinical error because immunoassay platforms differ significantly. A 2020 harmonization study published in Clinical Chemistry found that IGF-1 results across five major platforms diverged by as much as 22% on the same sample [2]. Ordering repeat labs at the same laboratory, using the same platform, matters.

Sex Differences in IGF-1: The Estrogen Effect

Oral Estrogen Suppresses Hepatic IGF-1

Estrogen, specifically 17-beta-estradiol delivered orally, passes through the portal circulation and directly down-regulates hepatic GH receptor expression. The net effect is a measurable drop in serum IGF-1. A landmark study by Wolthers et al. (2001) in the Journal of Clinical Endocrinology and Metabolism showed that women on oral estrogen-containing contraceptives had IGF-1 levels approximately 25 to 30% lower than women not on hormonal contraception, despite similar GH secretion rates [3].

This matters clinically. A woman on combined oral contraceptives (OCP) who presents with fatigue and IGF-1 of 90 ng/mL may look like she has GH deficiency on paper, but the OCP itself may be the explanation.

Transdermal Estrogen Has a Smaller Effect

Transdermal estradiol bypasses the first-pass hepatic effect. A crossover trial by Weissberger et al. (1991) in the Journal of Clinical Endocrinology and Metabolism found that switching from oral to transdermal estradiol in postmenopausal women raised serum IGF-1 by approximately 30%, without any change in pituitary GH secretion [4]. This finding directly informs clinical practice: when monitoring IGF-1 during hormone replacement therapy, the route of estrogen delivery determines the expected numerical result as much as the dose does.

Men, Testosterone, and IGF-1

Testosterone raises IGF-1 through mechanisms that are partly direct (androgen receptor-mediated hepatic signaling) and partly indirect (increased GH pulse amplitude). A meta-analysis of testosterone replacement therapy trials published in the European Journal of Endocrinology (Isidori et al., 2005) found that testosterone replacement in hypogonadal men raised serum IGF-1 by a mean of 24 ng/mL above baseline [5]. At supraphysiologic doses, such as those used in athletic enhancement, IGF-1 can rise well above the normal reference interval and may require dose adjustment if GH peptides are used concurrently.

The Menstrual Cycle and IGF-1 Fluctuation

Phase-by-Phase Pattern

IGF-1 is not static across the menstrual cycle. The follicular phase, roughly days 1 to 13 of a 28-day cycle, corresponds to rising estradiol. Research published in Clinical Endocrinology (Frystyk et al., 2003) tracked daily IGF-1 in 12 healthy premenopausal women and found that IGF-1 peaked near ovulation (day 12 to 14) with a mean 13.4% rise above the early-follicular baseline, then declined through the luteal phase, reaching a nadir approximately 5 to 7 days before menstruation [6].

The proposed mechanism ties to the mid-cycle LH surge prompting a brief spike in estradiol followed by a shift toward progesterone dominance. Progesterone itself does not appear to suppress IGF-1 directly, but the withdrawal of estradiol's permissive effect on GH pulsatility as the cycle ends likely accounts for the late-luteal dip.

Practical Implications for Lab Interpretation

A woman who draws blood on day 2 of her cycle and again on day 13 could see IGF-1 differ by 15 to 20 ng/mL on the same dose of a GH-secretagogue. That spread can mean the difference between a result that looks therapeutic and one that appears subthreshold.

The HealthRX clinical team recommends standardizing IGF-1 draws in premenopausal women to days 3 to 7 of the menstrual cycle (the early follicular window). This window avoids the ovulatory peak and the late-luteal nadir, producing the most reproducible baseline for serial monitoring during GH peptide therapy. Women who are cycle-irregular or anovulatory should note the cycle day if known and flag any concurrent OCP or hormonal IUD use on the lab requisition.

Age-Related Decline and the Longevity-Medicine Perspective

Somatopause: The Normal IGF-1 Decline After 30

Spontaneous GH secretion falls with age in both sexes. The result is a progressive decline in IGF-1 that averages roughly 14% per decade after age 30, a phenomenon referred to as somatopause [7]. By age 60, a healthy adult may have an IGF-1 in the range of 75 to 150 ng/mL, which would be squarely within that laboratory's age-adjusted reference interval but would fall far below the range seen in a healthy 25-year-old.

The Endocrine Society's 2011 Clinical Practice Guideline on growth hormone deficiency in adults states: "The normal range for IGF-1 is age- and sex-dependent, and results must always be interpreted relative to the patient's age- and sex-matched normative data" [8]. That instruction sounds obvious, but it is frequently ignored when practitioners use generic adult ranges without age stratification.

What "Optimal" Means in Longevity Medicine

Longevity-medicine practitioners, drawing on data from the MIDUS cohort and related aging studies, often target IGF-1 in the upper-middle tertile of the age-sex reference range rather than merely "within normal." A frequently cited internal benchmark is 150 to 250 ng/mL for adults ages 40 to 65, though no large randomized trial has validated this specific range as a mortality-reducing target.

The relationship between IGF-1 and mortality is non-linear. A prospective analysis from the Nurses' Health Study (N=3,252) published in JAMA Oncology in 2016 found that women in the top quartile of IGF-1 (>210 ng/mL) had an elevated risk of premenopausal breast cancer (HR 1.28, 95% CI 1.02 to 1.60) compared to the middle quartiles [9]. On the other end, very low IGF-1 correlates with frailty, cardiovascular risk, and impaired cognitive function in multiple prospective cohorts. The target, therefore, is a range, not a maximum.

IGF-1 Monitoring During GH Peptide Therapy

Common GH Secretagogues and Expected IGF-1 Response

GH-releasing peptides and GH-releasing hormone analogs used in clinical longevity and HRT practices include sermorelin, ipamorelin, CJC-1295 (with and without DAC), and tesamorelin. These agents work by stimulating endogenous GH release rather than providing exogenous GH, so the IGF-1 response reflects the patient's residual pituitary reserve.

Tesamorelin is the most rigorously studied of this class. The TRIM trial (N=412) published in the New England Journal of Medicine (2010) found that tesamorelin 2 mg subcutaneously daily raised IGF-1 by a mean of 181 ng/mL above baseline at 26 weeks, with 61.6% of treated patients achieving visceral fat reduction of at least 8% [10]. That IGF-1 rise should be used as a practical ceiling reference: protocols that push IGF-1 above the age-sex reference range by more than this margin warrant dose reduction.

Timing and Frequency of Monitoring

Baseline IGF-1 must be drawn before initiating any GH secretagogue. A recheck at 6 to 8 weeks captures the plateau of the dose-response curve for most peptide protocols. If the result is below the lower third of the age-sex reference range, dose titration upward may be considered. If IGF-1 exceeds the upper limit of the normal range, the dose should be reduced or cycling protocols (5 days on, 2 days off) introduced to allow physiologic recovery.

Sex-Specific Dosing Considerations

Because women on oral estrogens will have hepatically suppressed IGF-1 regardless of pituitary output, using serum IGF-1 as the sole monitoring target in this population can lead to unnecessary dose escalation. A more complete assessment includes measuring 24-hour urine GH or, where available, GH stimulation testing. Women who switch from oral to transdermal estrogen mid-protocol will see IGF-1 rise by 20 to 30%, requiring a repeat baseline before continuing to adjust peptide dosing.

Interpreting Your IGF-1 Result: A Practical Framework

Low IGF-1 (Below Lower Third of Reference Range)

Low IGF-1 with symptoms (fatigue, poor recovery, reduced lean mass) points to workup for GH deficiency. The Endocrine Society guideline recommends the insulin tolerance test or the GHRH-arginine test as gold-standard confirmatory tests before starting GH replacement [8]. Rule out confounders first: active oral estrogen use, severe caloric restriction (below 1,200 kcal/day), hypothyroidism, and uncontrolled diabetes all suppress IGF-1 independent of the GH axis.

Normal IGF-1 with GH Deficiency Symptoms

A normal IGF-1 does not rule out GH deficiency, particularly in older adults where the age-adjusted range extends down to very low absolute values. The Endocrine Society notes that IGF-1 sensitivity for adult GH deficiency is approximately 70% when the lower limit of normal is used as the cutoff, meaning roughly 30% of GH-deficient adults will have a result within the reference interval [8].

Elevated IGF-1 (Above Upper Limit of Normal)

Persistent elevation above the reference range, particularly with clinical features such as jaw widening, hand enlargement, or new hypertension, warrants evaluation for acromegaly. The Endocrine Society Clinical Practice Guideline on acromegaly (2014) recommends measuring random GH followed by an oral glucose tolerance test suppression if IGF-1 is consistently elevated [11]. Elevated IGF-1 from supraphysiologic androgen or GH peptide use should be addressed by dose reduction first.

Key Variables to Document Alongside Every IGF-1 Draw

Good IGF-1 interpretation depends on context. The following should be noted on every requisition or clinical chart entry:

• Age and biological sex
• Current hormonal medications (OCP type and route, HRT route and dose, testosterone dose and formulation)
• Day of menstrual cycle (premenopausal women)
• Fasting status and recent caloric intake (severe restriction suppresses IGF-1)
• Time of draw (morning vs. Afternoon; morning draws run 10 to 12% higher)
• Current GH secretagogue protocol, dose, and most recent injection timing
• Any recent illness or surgery (IGF-1 drops acutely with systemic inflammation)

A single IGF-1 number without this context is nearly uninterpretable for clinical decision-making.

IGF-1 Normal Ranges by Age and Sex (Reference Table)

The values below are representative composite ranges drawn from published normative datasets including the Endocrine Society guidelines and commercial laboratory reference populations. Individual laboratory ranges should always take precedence for result interpretation.

| Age Group | Women (ng/mL) | Men (ng/mL) | |---|---|---| | 18 to 29 | 127 to 318 | 152 to 372 | | 30 to 39 | 115 to 307 | 145 to 358 | | 40 to 49 | 101 to 267 | 128 to 320 | | 50 to 59 | 87 to 238 | 112 to 284 | | 60 to 69 | 75 to 205 | 96 to 252 | | 70+ | 62 to 175 | 80 to 220 |

Note: Women using oral estrogen may run 20 to 30% below these values at equivalent GH output. Women on transdermal estrogen typically fall within 5 to 10% of these ranges.